Otonomy to Present at Piper Jaffray Healthcare Conference
22. November 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
30. August 2017 07:00 ET
|
Otonomy, Inc.
Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpointsCompany to immediately suspend all development activities for OTIVIDEXCompany is also undertaking a review of its...
Otonomy Announces FDA Acceptance of OTIPRIO® Supplemental New Drug Application Filing for Acute Otitis Externa
18. Juli 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
05. Januar 2017 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update
03. November 2016 16:13 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update
04. August 2016 16:09 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
26. Januar 2016 07:05 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Added to NASDAQ Biotechnology Index
15. Dezember 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa
01. Dezember 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present at Piper Jaffray Healthcare Conference
24. November 2015 07:00 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...